

**SMG 1292.14**

**FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS**

**FOOD AND DRUG ADMINISTRATION**

**OFFICE OF MEDICAL PRODUCTS AND TOBACCO**

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**OFFICE OF GENERIC DRUGS**

**OFFICE OF BIOEQUIVALENCE**

**DIVISION OF CLINICAL REVIEW**

Effective Date: 01/24/2014

**1. DIVISION OF CLINICAL REVIEW (DKKNUBD).**

- A. Evaluates bioequivalence studies with clinical endpoints and protocols supporting Abbreviated New Drug Applications (ANDAs) and supplements to ANDAs.
- B. Recommends approval, disapproval, or new bioequivalence with clinical endpoints and/or protocols.
- C. Identifies potential clinical safety or product use issues or bioequivalence problems and provides guidance for resolving the matters.
- D. Reviews and evaluates drug disposition data and specialized drug delivery systems to assure bioequivalence of generic drug products.

**2. AUTHORITY AND EFFECTIVE DATE.**

The functional statements for this Division were approved by the Secretary of the Department of Health and Human Services and effective on January 24, 2014.